Description
Abemaxen 150 MG (Abemaciclib) is an oral cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor supplied as a 150 mg tablet in a 60’s pot and manufactured by Everest Pharmaceuticals. Its active ingredient, abemaciclib, selectively blocks CDK4 and CDK6 key enzymes that drive cancer cell proliferation preventing phosphorylation of the retinoblastoma protein (Rb) and arresting tumour cells in the G1 phase of the cell cycle. Abemaxen 150 MG (Abemaciclib) is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with endocrine therapy, and for HR+, HER2-, node-positive, high-risk early breast cancer in the adjuvant setting with endocrine therapy. The 150 mg twice-daily continuous dosing schedule is the reference-label standard combination dose, validated in the landmark MONARCH 3 trial where abemaciclib plus an aromatase inhibitor delivered a median progression-free survival (PFS) of 28.2 months versus 14.8 months on placebo. Searching for Abemaxen 150 MG Abemaciclib? Mediaid Pharmacy lists this product within its comprehensive breast cancer medicines portfolio, and ships it worldwide.
Basic Product Information of Abemaxen 150 MG (Abemaciclib)
| Brand Name | Abemaxen 150 MG (Abemaciclib) |
| Product Name | Abemaxen |
| Generic Name | Abemaciclib INN |
| Drug Class | Cyclin-Dependent Kinase 4 and 6 (CDK4/6) Inhibitor, Targeted Oncology Agent |
| Formulation | Tablet |
| Available Strength | 150 mg |
| Available Pack Size | 60’s Pot (60 tablets per pot) |
| Primary Indication | HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant; HR+, HER2-, node-positive, high-risk early breast cancer in the adjuvant setting with endocrine therapy |
| Manufacturer | Everest Pharmaceuticals |
| Originator Reference Brand | Verzenio / Verzenios (abemaciclib) by Eli Lilly and Company |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store in a dry place away from light and moisture, at the temperature printed on the pack. Keep out of the reach of children. |
How Abemaxen 150 MG (Abemaciclib) Works: CDK4/6 Inhibition in Breast Cancer
Abemaciclib, the active ingredient in Abemaxen 150 MG, is a selective, orally bioavailable small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) enzymes that function as critical gatekeepers of the mammalian cell cycle. A cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6 inhibitor) refers to a class of targeted oncology drugs that block the CDK4/6–cyclin D complex from phosphorylating the retinoblastoma protein (Rb), thereby preventing tumour cells from advancing from the G1 growth phase into the DNA synthesis (S) phase of the cell cycle. Abemaciclib binds to CDK4 and CDK6 in an ATP-competitive, reversible manner, producing a durable suppression of phosphorylated Rb (pRb) and halting cell proliferation.
In hormone receptor-positive (HR+) breast cancer, the CDK4/6–cyclin D pathway is frequently dysregulated through amplification of CDK4, loss of the endogenous CDK inhibitor p16 (CDKN2A), or overexpression of cyclin D1 driving unchecked tumour cell division and contributing to endocrine therapy resistance. Abemaciclib is distinctive among approved CDK4/6 inhibitors in that it is dosed continuously twice daily rather than on a 3-weeks-on/1-week-off schedule, sustaining uninterrupted target suppression. Beyond G1 arrest, preclinical data demonstrate that prolonged abemaciclib exposure induces cellular senescence, apoptosis, and metabolic reprogramming in oestrogen receptor-positive (ER+) breast cancer cells, contributing to tumour regression in xenograft models. Oncologists building comprehensive breast cancer treatment programmes can review the complete range of breast cancer medicines at Mediaid Pharmacy for companion and supportive therapies.
In the pivotal MONARCH 3 trial for first-line HR+, HER2- advanced breast cancer, abemaciclib at 150 mg twice daily combined with a nonsteroidal aromatase inhibitor (anastrozole or letrozole) delivered a median progression-free survival (PFS) of 28.2 months versus 14.8 months on placebo plus aromatase inhibitor (hazard ratio 0.525; 95% CI 0.415–0.665; p<0.0001). The objective response rate (ORR) in patients with measurable disease was 59% in the abemaciclib arm versus 44% in the placebo arm (p=0.004). The 150 mg twice-daily continuous dose is the reference-label standard starting dose for abemaciclib used in combination with endocrine therapy, as validated across the MONARCH 2, MONARCH 3, and monarchE Phase III programmes.
Approved Indications of Abemaciclib (Reference Label for Abemaxen 150 MG (Abemaciclib))
Abemaciclib, the active ingredient in Abemaxen 150 MG, is approved internationally across two distinct breast cancer settings advanced/metastatic disease and high-risk early-stage disease in adult patients with hormone receptor-positive, HER2-negative tumours. Prescribers should confirm the exact locally approved indications on the Abemaxen product label before initiating therapy.
|
HR+, HER2- Advanced or Metastatic Breast Cancer In Combination with Endocrine Therapy or as Monotherapy Indicated as initial endocrine-based therapy in combination with an aromatase inhibitor for postmenopausal women with HR+, HER2- advanced or metastatic breast cancer (MONARCH 3); in combination with fulvestrant for adults with HR+, HER2- advanced or metastatic breast cancer with disease progression on or after prior endocrine therapy (MONARCH 2, PFS 16.4 months vs 9.3 months on fulvestrant alone); and as monotherapy for adults with HR+, HER2- metastatic breast cancer that has progressed after endocrine therapy and prior chemotherapy in the metastatic setting (MONARCH 1). |
HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer Adjuvant Treatment with Endocrine Therapy Abemaciclib is the first and only CDK4/6 inhibitor approved in the adjuvant setting for adults with HR+, HER2-, node-positive early breast cancer at high risk of recurrence, used in combination with endocrine therapy for 2 years. The monarchE Phase III trial (5,637 patients) demonstrated a 7.6% absolute improvement in invasive disease-free survival (IDFS) and a 6.7% improvement in distant relapse-free survival (DRFS) at 5 years versus endocrine therapy alone, with benefits persisting as a carryover effect beyond the 2-year treatment period. |
Key Clinical Benefits of Abemaxen 150 MG (Abemaciclib)
|
Nearly Doubled PFS in First-Line Advanced Breast Cancer The MONARCH 3 trial demonstrated a median PFS of 28.2 months with abemaciclib 150 mg twice daily plus an aromatase inhibitor, compared with 14.8 months on placebo plus an aromatase inhibitor (HR 0.525; p<0.0001) representing a near-doubling of progression-free time and establishing abemaciclib-based combination therapy as a first-line standard of care for HR+, HER2- advanced breast cancer. |
Sustained Adjuvant Benefit Beyond the 2-Year Treatment Period The monarchE trial’s 5-year analysis (median follow-up 4.5 years) confirmed a carryover effect of abemaciclib after treatment completion, with a 7.6% absolute IDFS improvement and a 6.7% DRFS improvement versus endocrine therapy alone demonstrating that 2 years of abemaciclib continues to reduce recurrence risk well beyond the active dosing period in high-risk node-positive early breast cancer. |
First CDK4/6 Inhibitor Approved as Single-Agent Monotherapy Abemaciclib is the first CDK4/6 inhibitor to receive approval as monotherapy, based on the MONARCH 1 trial in heavily pre-treated HR+, HER2- metastatic breast cancer patients, where single-agent abemaciclib produced an objective response rate of 19.7% and a clinical benefit rate of 42.4% demonstrating intrinsic anti-tumour activity beyond its role as an endocrine sensitiser. |
Dosage and Administration of Abemaxen 150 MG (Abemaciclib)
Administration Rule Can Be Taken With or Without Food: Unlike many targeted therapies, abemaciclib may be taken with or without food. Swallow Abemaxen 150 MG tablets whole with water. Do not crush, split, or chew the tablets. Doses should be taken at approximately the same times each day to maintain consistent plasma drug levels. If a dose is vomited or missed, do not take an additional dose resume the normal dosing schedule with the next scheduled dose.
HR+, HER2- Advanced or Metastatic Breast Cancer Standard Combination Dose (150 mg Twice Daily): The reference label recommends 150 mg twice daily (BID) on a continuous schedule when abemaciclib is used in combination with an aromatase inhibitor (letrozole or anastrozole) or with fulvestrant. Abemaxen 150 MG tablets administered twice daily morning and evening provide the full 300 mg daily dose validated in the MONARCH 2 and MONARCH 3 Phase III trials. Abemaciclib is continued until disease progression or unacceptable toxicity.
HR+, HER2- Advanced or Metastatic Breast Cancer Monotherapy Dose (200 mg Twice Daily): When abemaciclib is used as monotherapy for pre-treated metastatic breast cancer, the reference label recommends 200 mg twice daily. Note that Abemaxen is available in 150 mg strength; the treating oncologist will confirm the appropriate strength and number of tablets for monotherapy use. Do not self-adjust the dose.
HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer Adjuvant Setting (150 mg Twice Daily for 2 Years): In the adjuvant setting, abemaciclib is administered at 150 mg twice daily for 2 years in combination with standard adjuvant endocrine therapy (aromatase inhibitor or tamoxifen), with endocrine therapy continuing for at least 5 years total as clinically indicated. Treatment is discontinued after 2 years, upon disease recurrence, or upon unacceptable toxicity.
Dose Reduction Schedule for Toxicity Management: If abemaciclib-related adverse events (particularly diarrhoea, neutropenia, or hepatotoxicity) require dose modification, the reference label specifies a stepwise reduction: first to 100 mg twice daily, then to 50 mg twice daily if further reduction is necessary. Dose modifications are guided by the treating oncologist based on NCI Common Terminology Criteria for Adverse Events (CTCAE) grading.
Dose Adjustment for CYP3A4 Inhibitors: When a strong CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, itraconazole) must be co-administered, the reference label recommends reducing the abemaciclib dose to 100 mg twice daily. Strong and moderate CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine) significantly reduce abemaciclib plasma exposure and should be avoided. Consult the treating oncologist before initiating or discontinuing any concomitant medication.
Clinical Monitoring Requirements During Abemaxen 150 MG (Abemaciclib) Treatment
Haematological monitoring is the primary ongoing safety requirement for abemaciclib therapy. The reference label mandates complete blood count (CBC) assessment before initiating treatment, every 2 weeks for the first 2 months, monthly for the next 2 months, and then as clinically indicated. Neutropenia a reduction in circulating neutrophil count was the most frequent Grade 3 or 4 adverse event in MONARCH 3 (21.1% of patients in the abemaciclib arm). Abemaciclib should be withheld for Grade 3 neutropenia until recovery to Grade 1 or baseline, then restarted at the next lower dose level. Febrile neutropenia requires permanent discontinuation in most cases.
Liver function tests (ALT, AST, and bilirubin) must be performed before initiating treatment, every 2 weeks for the first 2 months, monthly for the following 2 months, and as clinically indicated thereafter. If ALT or AST elevation reaches Grade 3 or higher without total bilirubin elevation, abemaciclib should be withheld until recovery and restarted at the next lower dose level. Concurrent elevation of ALT or AST above 3× the upper limit of normal with total bilirubin above 2× the upper limit of normal (in the absence of cholestasis) requires permanent discontinuation. Diarrhoea monitoring and proactive management beginning with loperamide at first loose stool are critical; Grade 3 or 4 diarrhoea or persistent Grade 2 diarrhoea requires dose modification. Monitoring for venous thromboembolic events (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), and for signs of interstitial lung disease (ILD) or pneumonitis should be integrated into each clinical review throughout the treatment period.
Drug Interactions and Important Safety Information for Abemaxen 150 MG (Abemaciclib)
The most clinically consequential drug interaction for abemaciclib involves inhibitors and inducers of CYP3A4, the primary cytochrome P450 enzyme responsible for abemaciclib metabolism. Strong CYP3A4 inhibitors including ketoconazole, itraconazole, clarithromycin, and ritonavir-based antiretroviral regimens significantly increase abemaciclib plasma exposure and systemic toxicity risk; when co-administration is unavoidable, the abemaciclib dose must be reduced to 100 mg twice daily and patients monitored closely for adverse events. Strong CYP3A4 inducers including rifampicin, carbamazepine, phenytoin, and St John’s Wort substantially decrease abemaciclib plasma concentrations and may render therapy sub-therapeutic; the reference label recommends avoiding these combinations entirely where clinically feasible.
Abemaciclib and its active metabolites inhibit the renal transporters OCT1, OCT2, MATE1, and MATE2-K, which are responsible for the active tubular secretion of certain medications including metformin. Co-administration with metformin may increase metformin plasma levels, potentially altering glycaemic control in diabetic patients; clinical review and blood glucose monitoring are advisable. Abemaciclib does not have a clinically relevant food interaction it may be taken with or without meals which is an important practical advantage over many targeted oncology agents. Patients must inform their oncologist of all concomitant medications, including over-the-counter drugs, herbal supplements, and antacids, before and during Abemaxen 150 MG treatment. Those requiring adjuvant hormonal agents alongside abemaciclib can contact the Mediaid Pharmacy team for sourcing; the full range of oncology medicines available for worldwide dispatch is listed on the Mediaid Pharmacy website.
Side Effects and Precautions of Abemaxen 150 MG (Abemaciclib)
|
Common Side Effects Diarrhoea (most common; reported in ~81% of MONARCH 3 patients predominantly Grade 1–2) Neutropenia and leukopenia (Grade 3/4 neutropenia in 21.1% in MONARCH 3) Fatigue and asthenia Nausea and vomiting Abdominal pain and discomfort Infections (upper and lower respiratory tract) Anaemia Alopecia (hair thinning or loss) Decreased appetite and weight loss Elevated liver enzymes (ALT and AST) |
Serious Warnings and Precautions Neutropenia: CBC monitoring is mandatory before initiation and throughout treatment. Febrile neutropenia requires immediate medical review and may necessitate permanent discontinuation. Hepatotoxicity: monitor liver function tests at baseline, every 2 weeks for the first 2 months, and monthly thereafter. Concurrent Grade 3+ ALT/AST elevation with bilirubin elevation requires permanent discontinuation. Venous thromboembolic events (VTE): pulmonary embolism (PE) and deep vein thrombosis (DVT) have been reported. Monitor for signs and symptoms at every clinical visit; initiate appropriate anticoagulation when VTE is confirmed. Interstitial lung disease (ILD) / pneumonitis: cases including fatalities have been reported. Monitor for new or worsening pulmonary symptoms; permanently discontinue for Grade 3 or 4 ILD. Embryo-fetal toxicity: abemaciclib can cause fetal harm based on its mechanism of action. Females of reproductive potential must use effective contraception during treatment and for at least 3 weeks after the final dose. Males with female partners of reproductive potential must use contraception during treatment and for 3 months after the last dose. Breastfeeding is not recommended during treatment and for 3 weeks after the final dose. |
Who Should Use Abemaxen 150 MG (Abemaciclib)?
Abemaxen 150 MG (Abemaciclib) is the reference-label combination dose strength for adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer receiving abemaciclib alongside an aromatase inhibitor or fulvestrant, and for adults with HR+, HER2-, node-positive, high-risk early breast cancer in the adjuvant setting with endocrine therapy. The 150 mg twice-daily continuous dosing schedule is the dose validated across the landmark MONARCH 2, MONARCH 3, and monarchE Phase III trials ensuring that every prescription initiated at this strength is grounded in Level 1 clinical evidence. Oncologists assess baseline CBC, liver function, and signs or symptoms of VTE and ILD before initiating Abemaxen 150 MG. Patients who are pregnant, breastfeeding, or of reproductive potential require counselling on contraception requirements before treatment begins. For patients requiring complementary targeted therapies or supportive oncology treatments alongside abemaciclib, Mediaid Pharmacy’s oncology specialty medicines range provides a broad selection of approved agents available for global delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Abemaxen 150 MG (Abemaciclib)
Mediaid Pharmacy is a Dhaka-based supplier of oncology and specialty medicines with worldwide shipping. Abemaxen 150 MG (Abemaciclib) is available in a 60’s pot tablet pack, and all orders are supported by pricing quotations, stock confirmation, regulatory documentation, and end-to-end delivery tracking. Hospitals, specialist oncology clinics, distributors, and patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all enquiries about Abemaxen 150 MG Abemaciclib stock, pricing, and international delivery timelines. Buyers sourcing multiple oncology or breast cancer medicines in a single shipment can browse the complete breast cancer medicines collection before requesting a consolidated quotation.
Why Choose Abemaxen 150 MG (Abemaciclib) from Mediaid Pharmacy?
Abemaxen 150 MG (Abemaciclib) provides oncology teams with a 150 mg abemaciclib tablet in a 60’s pot the dose strength that anchored the MONARCH 3 trial (median PFS 28.2 months versus 14.8 months on placebo plus aromatase inhibitor; HR 0.525; p<0.0001) and the monarchE adjuvant trial (7.6% absolute IDFS improvement at 5 years versus endocrine therapy alone). The 150 mg twice-daily continuous schedule is the reference-label standard for abemaciclib used in combination with endocrine therapy across advanced and early breast cancer settings, ensuring every initiated prescription is grounded in validated, published Phase III evidence. Manufactured by Everest Pharmaceuticals, Abemaxen is an accessible oncology-grade tablet formulation suitable for patients requiring continuous twice-daily CDK4/6 inhibition. Mediaid Pharmacy supplies Abemaxen 150 MG in 60’s pot packs with full product documentation, specialist supply support, and worldwide shipping from Dhaka. Every order begins with a prescription-based enquiry that maintains supply aligned with clinical need. To compare abemaciclib with other targeted breast cancer or oncology agents, or to source additional cancer therapies, visit the Mediaid Pharmacy oncology medicines section and contact the team for a personalised quotation.
Frequently Asked Questions About Abemaxen 150 MG (Abemaciclib)
What is Abemaxen 150 MG (Abemaciclib) used for?
Abemaxen 150 MG (Abemaciclib) is an oral CDK4/6 inhibitor used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in adults. It is indicated in combination with an aromatase inhibitor as initial therapy for advanced or metastatic breast cancer in postmenopausal women, in combination with fulvestrant for advanced or metastatic disease that has progressed on prior endocrine therapy, and in combination with endocrine therapy for 2 years in the adjuvant setting for adults with HR+, HER2-, node-positive, high-risk early breast cancer. Abemaciclib blocks CDK4 and CDK6, preventing tumour cells from progressing through the cell cycle and driving cancer cell growth arrest, senescence, and apoptosis.
What is the generic name of Abemaxen 150 MG?
The generic name of Abemaxen 150 MG is abemaciclib INN. Abemaxen 150 MG is a tablet formulation available in a 60’s pot, manufactured by Everest Pharmaceuticals. The originator reference brand for abemaciclib is Verzenio in the United States and Verzenios in Europe and other international markets, both developed and commercialised by Eli Lilly and Company.
What is the standard dosing of Abemaxen 150 MG (Abemaciclib) for advanced breast cancer?
The dose must always be determined by your treating oncologist or specialist physician. The reference label for abemaciclib recommends 150 mg twice daily (BID) on a continuous schedule when used in combination with an aromatase inhibitor or with fulvestrant for HR+, HER2- advanced or metastatic breast cancer. In the adjuvant setting for high-risk early breast cancer, abemaciclib is given at 150 mg twice daily for 2 years alongside endocrine therapy. If adverse events require dose reduction, the reference label specifies stepwise reductions to 100 mg twice daily, then 50 mg twice daily. Never change your dose without direction from your prescribing oncologist.
What strengths and pack sizes is Abemaxen (Abemaciclib) available in?
Abemaxen is available as a 150 mg tablet in a 60’s pot (60 tablets per pot), manufactured by Everest Pharmaceuticals. Contact Mediaid Pharmacy for current stock availability, pricing, and worldwide shipping details.
What are the side effects of Abemaxen 150 MG (Abemaciclib)?
Common side effects of abemaciclib 150 mg include diarrhoea (affecting approximately 81% of patients in MONARCH 3, primarily Grade 1–2), neutropenia (Grade 3/4 in 21.1%), fatigue, nausea, abdominal pain, infections, anaemia, vomiting, alopecia, decreased appetite, leukopenia, and elevated liver enzymes. Serious but less frequent adverse effects include Grade 3/4 neutropenia with or without fever (requiring dose modification or discontinuation), clinically significant hepatotoxicity, venous thromboembolic events (including DVT and pulmonary embolism), interstitial lung disease or pneumonitis (including fatal cases), and embryo-fetal toxicity. Mandatory complete blood count monitoring, liver function testing, and clinical assessment for VTE and ILD are required throughout the treatment period. Consult your prescribing oncologist about your individual risk profile before and during treatment.
Does Abemaxen 150 MG (Abemaciclib) need to be taken on an empty stomach?
No. Unlike some targeted oncology drugs, abemaciclib can be taken with or without food. This is a clinically important practical advantage, as food intake does not meaningfully affect abemaciclib pharmacokinetics. Abemaxen 150 MG tablets should be swallowed whole with water at approximately the same times each day (e.g., morning and evening) to maintain consistent plasma drug levels. Do not crush, split, or chew the tablets. If a dose is missed or vomited, skip that dose and resume the next scheduled dose at the normal time do not double the dose.
How often are blood tests required during Abemaxen 150 MG treatment?
The reference label requires complete blood count (CBC) assessment before initiating treatment, every 2 weeks for the first 2 months, monthly for the following 2 months, and then as clinically indicated. Liver function tests (ALT, AST, and bilirubin) must be performed at baseline, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically warranted thereafter. Clinical evaluation for signs and symptoms of venous thromboembolism and interstitial lung disease or pneumonitis should be part of every routine oncology review throughout the treatment course.
Is Abemaxen 150 MG (Abemaciclib) safe during pregnancy or while breastfeeding?
No. Abemaciclib can cause fetal harm based on its mechanism of action (CDK4/6 inhibition disrupts normal cell cycle progression in developing fetal tissues). Females of reproductive potential must use effective contraception during treatment with Abemaxen 150 MG and for at least 3 weeks after the final dose. Males with female partners of reproductive potential must use contraception during treatment and for 3 months after the last dose. Breastfeeding is not recommended during treatment and for 3 weeks after the final dose. Speak with your prescribing oncologist or specialist physician before starting treatment if you are pregnant, planning a pregnancy, or currently breastfeeding.
Can I order Abemaxen 150 MG (Abemaciclib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Abemaxen 150 MG (Abemaciclib) to patients and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order Abemaxen 150 MG (Abemaciclib) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.